Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia

Inclusion Criteria: * Age 18 years or older at time of CT initiation * Signed informed consent * Patients with diagnosis of breast cancer,lymphoma or leukemia (including autografted subjects) * Planned, ongoing or completed (within last 5 years) chemotherapy with anthracycline * Left ventricular ejection fraction (LVEF) ≥50% pre-chemotherapy * The participant is willing to undergo CMR scans and all other required study procedures Exclusion Criteria: * Known cardiomyopathy and/or LVEF \<50% * Known heart failure * History of myocardial infarction (MI) * Clinically significant cardiac valvular disease * Clinically significant pericardial effusion * Allografted subjects * Contraindications to CMR testing (Cohort A \& prospective evaluation for Cohort B): * Pacemakers, other metallic implants or severe claustrophobia * Weight \> 135 kg * Patients with a history of previous allergic reaction to gadolinium * Patients with history of seizure * Renal insufficiency (eGFR of \< 45ml/min/1.73m2 using the MDRD equation) * Pregnant or breastfeeding women